Search
Close this search box.

You are here:  

BitMEX Launches 20 New Altcoin Options Featuring LTC, SUI, LINK, and More

BitMEX Launches 20 New Altcoin Options Traders can now access 20 new altcoin options contracts for Litecoin, Sui, Chainlink, Aave, and more on BitMEX MAHE, Seychelles, Feb. 05, 2025 (GLOBE NEWSWIRE) — BitMEX, the OG crypto derivatives exchange, is excited to announce the launch of 20 new option contracts, offering traders one of the first-ever opportunities […]

READ MORE …

BitMEX Launches 20 New Altcoin Options Featuring LTC, SUI, LINK, and More

BitMEX Launches 20 New Altcoin Options Traders can now access 20 new altcoin options contracts for Litecoin, Sui, Chainlink, Aave, and more on BitMEX MAHE, Seychelles, Feb. 05, 2025 (GLOBE NEWSWIRE) — BitMEX, the OG crypto derivatives exchange, is excited to announce the launch of 20 new option contracts, offering traders one of the first-ever opportunities […]

READ MORE …

BitMEX Launches 20 New Altcoin Options Featuring LTC, SUI, LINK, and More

BitMEX Launches 20 New Altcoin Options Traders can now access 20 new altcoin options contracts for Litecoin, Sui, Chainlink, Aave, and more on BitMEX MAHE, Seychelles, Feb. 05, 2025 (GLOBE NEWSWIRE) — BitMEX, the OG crypto derivatives exchange, is excited to announce the launch of 20 new option contracts, offering traders one of the first-ever opportunities […]

READ MORE …

BitMEX Launches 20 New Altcoin Options Featuring LTC, SUI, LINK, and More

BitMEX Launches 20 New Altcoin Options Traders can now access 20 new altcoin options contracts for Litecoin, Sui, Chainlink, Aave, and more on BitMEX MAHE, Seychelles, Feb. 05, 2025 (GLOBE NEWSWIRE) — BitMEX, the OG crypto derivatives exchange, is excited to announce the launch of 20 new option contracts, offering traders one of the first-ever opportunities […]

READ MORE …

Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases

– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function- -Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025- -Topline results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025- – Enrollment of Phase […]

READ MORE …

Latest Post

Advertisment